You are here

Article info

Article menu
Immunotherapy biomarkers
Original research
Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma

Authors

  • Judith M Versluis Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Stephanie A Blankenstein Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Petros Dimitriadis Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • James S Wilmott Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia Melanoma Institute Australia, Sydney, New South Wales, Australia Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia PubMed articlesGoogle scholar articles
  • Robert Elens Core Facility Molecular Pathology and Biobanking, Netherlands Cancer Institute, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Willeke A M Blokx Department of Pathology, UMC Utrecht, Utrecht, The Netherlands PubMed articlesGoogle scholar articles
  • Winan van Houdt Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Alexander Maxwell Menzies Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia Melanoma Institute Australia, Sydney, New South Wales, Australia Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, NSW, Australia PubMed articlesGoogle scholar articles
  • Yvonne M Schrage Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Michel W J M Wouters Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands Department of Biomedical Data Science, Leiden University Medical Center, Leiden, The Netherlands PubMed articlesGoogle scholar articles
  • Joyce Sanders Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Annegien Broeks Core Facility Molecular Pathology and Biobanking, Netherlands Cancer Institute, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Richard A Scolyer Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia Melanoma Institute Australia, Sydney, New South Wales, Australia Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia PubMed articlesGoogle scholar articles
  • Karijn P M Suijkerbuijk Department of Medical Oncology, UMC Utrecht, Utrecht, The Netherlands PubMed articlesGoogle scholar articles
  • Georgina V Long Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia Melanoma Institute Australia, Sydney, New South Wales, Australia Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, NSW, Australia PubMed articlesGoogle scholar articles
  • Alexander C J van Akkooi Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia Melanoma Institute Australia, Sydney, New South Wales, Australia Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia PubMed articlesGoogle scholar articles
  • Christian U Blank Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands PubMed articlesGoogle scholar articles

Citation

Versluis JM, Blankenstein SA, Dimitriadis P, et al
Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma
Journal for ImmunoTherapy of Cancer 2024;12:e008125. doi: 10.1136/jitc-2023-008125
Online issue publication 
April 27, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.